Daratumumab, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma
Status:
Recruiting
Trial end date:
2025-06-30
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well daratumumab, pomalidomide, and dexamethasone work in
treating patients with multiple myeloma that has come back (relapsed). Immunotherapy with
daratumumab may induce changes in body's immune system and may interfere with the ability of
cancer cells to grow and spread. Drugs used in chemotherapy, such as pomalidomide and
dexamethasone, work in different ways to stop the growth of cancer cells, either by killing
the cells, by stopping them from dividing, or by stopping them from spreading. Giving
daratumumab with dexamethasone and pomalidomide may work bettering in treating patient
compared to dexamethasone and pomalidomide alone.
Phase:
Phase 2
Details
Lead Sponsor:
Academic and Community Cancer Research United
Collaborators:
Janssen Scientific Affairs, LLC National Cancer Institute (NCI)